VEGFA and colorectal carcinoma: In the past decade, targeted biologic therapies, including monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have significantly improved clinical outcomes in patients with CRC [5].